MedTrace Logo

Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis

NCT02085395 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-03-14

No results posted yet for this study

Summary

To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's Disease) reduced at least 75%.

Conditions

  • Actinic Keratosis
  • Bowen's Disease

Interventions

DRUG

SR-T100 ® Gel

Sponsors & Collaborators

  • G&E Herbal Biotechnology Co., LTD

    lead INDUSTRY

Principal Investigators

  • Dr. Hamm-Ming Sheu, MD · Department of Dermatology National Cheng Kung University Hospital Tainan, Taiwan, ROC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-04-30
Completion
2010-11-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02085395 on ClinicalTrials.gov